Opioid antagonists: all 625 studies that test it

Page 1 of 7. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.

• The Study of Brave-LC LDN Treatment TrialNot yet recruitingNCT07916259Phase 3
• A Pilot Study on the Efficacy of Oral Low Dose Naltrexone for VulvodyniaNot yet recruitingNCT07862400Phase 2
• Naloxone for In-Hospital Cardiac ArrestNot yet recruitingNCT07806565Phase 2/3
• Naltrexone for Nonsuicidal Self-InjuryNot yet recruitingNCT07641283Not applicable
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaRecruitingNCT07615426Phase 1
• Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility TrialRecruitingNCT07439549Phase 4
• Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use DisorderNot yet recruitingNCT07433413Phase 3
• A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery PatientsNot yet recruitingNCT07398404Phase 1/2
• Low-Dose Naltrexone For ME/CFS: Dose-FindingNot yet recruitingNCT07285473Phase 2
• Combination Therapy for Alcohol Use DisorderNot yet recruitingNCT07249554Phase 2
• Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery PatientsNot yet recruitingNCT07224087Phase 1
• Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)RecruitingNCT07224009Phase 2
• Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)Enrolling by invitationNCT07221565Phase 1/2
• Individualized Pharmacological Approach to Obesity in Patients With Bipolar DisorderRecruitingNCT07213466Phase 4
• Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-CessationRecruitingNCT07092618Phase 2/3
• TH104 for the Treatment of Pruritus in Primary Biliary CholangitisNot yet recruitingNCT06733519Phase 2
• Sedation and Guided Education for Depression StudyNot yet recruitingNCT06705270Not applicable
• Endogenous Opioid Response to InjectionsRecruitingNCT06666621Phase 4
• Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injuryNot yet recruitingNCT06622239Phase 2
• Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release TabletRecruitingNCT06620562Phase 4
• Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use DisorderRecruitingNCT06426303Phase 4
• LIFT: Life Improvement TrialRecruitingNCT06366724Phase 2
• Low Dose Naltrexone Therapy for Complex Regional Pain SyndromeEnrolling by invitationNCT06306157Phase 4
• Naloxone for Opioid Associated Out of Hospital Cardiac ArrestNot yet recruitingNCT06251609Phase 2
• Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence.Not yet recruitingNCT06175507Not applicable
• Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.RecruitingNCT06162377Phase 4
• Effectiveness of Low-dose Naltrexone in Patients With Different Types of VulvodyniaRecruitingNCT05955313Phase 2
• Exploring the PK of Different Doses of Naltrexone in Patients With AUDRecruitingNCT05919017Phase 1
• Emergency Department-Initiated Medications for Alcohol Use DisorderRecruitingNCT05827159Phase 3
• NAlmefene Versus Placebo in Addition to Treatment As Usual on Craving in Behavioural AddictionsRecruitingNCT05540288Phase 3
• Low Dose Naltrexone for Pain in Patients With HIVRecruitingNCT05537935Phase 4
• RM1 Project 1 - tAN NaloxoneRecruitingNCT05490134Early Phase 1
• Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent PersonsNot yet recruitingNCT05382091Phase 2
• Low Dose Naltrexone Use in Patients With POTSNot yet recruitingNCT05363514Phase 4
• Bridging ED to Outpatient AUD Therapy With NaltrexoneNot yet recruitingNCT05228418Phase 4
• Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use DisorderRecruitingNCT05011266Phase 2/3
• Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency DepartmentsRecruitingNCT04893525Phase 2/3
• Chronic Widespread Pain in HIV: Novel Mechanisms and TherapeuticsRecruitingNCT04787848Not applicable
• Low-Dose Naltrexone for the Treatment of Painful Diabetic NeuropathyRecruitingNCT04678895Phase 2
• Predicting Response to Naltrexone With Eye Tracking in Gaming DisorderRecruitingNCT04649892Phase 2
• A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use DisorderRecruitingNCT04375033Phase 4
• Opioids and Social Support Enhanced Extinction EffectsEnrolling by invitationNCT04166071Early Phase 1
• Low-Dose Naltrexone for the Treatment of Complex Regional Pain SyndromeRecruitingNCT02502162Not applicable
• Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mgCompletedNCT06719986Phase 1Results posted
• A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and PleasureTerminatedNCT06635135Phase 3Results posted
• Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.CompletedNCT06306391Phase 1Results posted
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyCompletedNCT05550532Phase 3Results posted
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)TerminatedNCT05518149Phase 3Results posted
• A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyCompletedNCT05455684Phase 3Results posted
• Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing RegimensCompletedNCT05219669Phase 1Results posted
• Vaped Marijuana to Attenuate Naloxone-Precipitated WithdrawalTerminatedNCT05114460Phase 2Results posted
• Oral Naltrexone In Pediatric Eating DisordersTerminatedNCT05073679Phase 2/3Results posted
• Opioid Antagonism in Hypogonadotropic HypogonadismCompletedNCT04975334Phase 1Results posted
• Naltrexone NeuroimagingCompletedNCT04935931Early Phase 1Results posted
• Opioid Modulation and Neural Reward Activation in Healthy AdultsCompletedNCT04854551Phase 1/2Results posted
• Pharmacodynamic Evaluation of Intranasal NalmefeneCompletedNCT04828005Phase 1Results posted
• Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSMCompletedNCT04791969Phase 2Results posted
• Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal NaloxoneCompletedNCT04764630Phase 1Results posted
• Pharmacokinetic Evaluation of Intranasal NalmefeneCompletedNCT04759768Phase 1Results posted
• Impact of Colchicine and Low-dose Naltrexone on COVID-19CompletedNCT04756128Phase 2Results posted
• Pharmacokinetic Study of Vivitrol in Healthy ParticipantsCompletedNCT04716881Phase 1Results posted
• Inpatient Single Dose Interventions for Alcohol Use DisorderCompletedNCT04562779Early Phase 1Results posted
• Naltrexone Treatment for Prolonged Grief Disorder (PGD)TerminatedNCT04547985Phase 4Results posted
• EMI-EHP Weight Management and Type 2 Diabetes Pragmatic TrialTerminatedNCT04531176Phase 4Results posted
• Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1TerminatedNCT04480554Phase 2Results posted
• The Effect of Chronic Pain on Delay Discounting in Methadone PatientsTerminatedNCT04473950Phase 1Results posted
• Low-dose Naltrexone for Bladder Pain SyndromeTerminatedNCT04450316Phase 2Results posted
• Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing AlopeciaCompletedNCT04409041Phase 2Results posted
• Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19TerminatedNCT04365985Phase 2Results posted
• Study of Naltrexone-Induced Blockade of Antidepressant EffectsCompletedNCT04322526Phase 4Results posted
• IC PaIN Trial: Interstitial Cystitis Pain Improvement With NaltrexoneTerminatedNCT04313972Phase 4Results posted
• Increasing Naloxone Access for Persons Who Use OpioidsCompletedNCT04303000Phase 4Results posted
• A Novel Human Lab Model for Screening AUD MedicationsCompletedNCT04249882Phase 2Results posted
• Vivitrol Treatment for Cannabis Use DisorderTerminatedNCT04139668Phase 2Results posted
• Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use DisorderTerminatedNCT04094584Phase 4Results posted
• St. PETERsburg Pain and Alcohol Intervention With Naltrexone and GabapentinCompletedNCT04052139Phase 2Results posted
• Chronic Low Back Pain and MeditationCompletedNCT04034004Early Phase 1Results posted
• Low-Dose Naltrexone in Combination With Standard Treatment in Women With EndometriosisTerminatedNCT03970330Phase 3Results posted
• Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-RespondersCompletedNCT03946111Phase 2/3Results posted
• Rapid Initiation of Drug Treatment EngagementCompletedNCT03908437Phase 4Results posted
• Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSDTerminatedNCT03852628Phase 2Results posted
• Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus PreventionCompletedNCT03852524Phase 2Results posted
• The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy VolunteersCompletedNCT03810495Phase 1Results posted
• Treatment of Chronic Itch in Patients Under Arsenic Exposure With NaloxoneCompletedNCT03751111Phase 1/2Results posted
• Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent IndividualsTerminatedNCT03711318Phase 3Results posted
• Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic SubjectsCompletedNCT03660475Phase 2Results posted
• Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)TerminatedNCT03608163Phase 4Results posted
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of DepressionCompletedNCT03559192Phase 2Results posted
• Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced ConstipationCompletedNCT03523520Phase 4Results posted
• Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in ChildrenCompletedNCT03447782Phase 1/2Results posted
• The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major DepressionCompletedNCT03386448Phase 4Results posted
• Linking Infectious and Narcology Care-Part IICompletedNCT03290391Phase 4Results posted
• St. PETERsburg Pain and Alcohol Intervention With Naltrexone and NalmefeneCompletedNCT03278886Phase 1/2Results posted
• Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-UpCompletedNCT03275350Phase 2/3Results posted
• Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075CompletedNCT03248947Early Phase 1Results posted
• Ancillary Effects of Oral Naloxegol (Movantik)CompletedNCT03235739Phase 4Results posted
• A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine RespondersCompletedNCT03232346Phase 3Results posted
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831CompletedNCT03201757Phase 3Results posted
• The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen CombinationCompletedNCT03194555Phase 2Results posted
• Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderCompletedNCT03187769Phase 3Results posted

← Opioid antagonists overview